Non-Alcoholic Fatty Liver Disease (NAFLD) is a common, yet complex, hepatic disorder that is emerging as a global health burden. It is a spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Understanding its causes, diagnostic methods, and modern therapeutic approaches is vital for effective patient management.
Although the pathogenesis of NAFLD is multifactorial, insulin resistance and metabolic syndrome are considered central to its development. Other factors include genetics, diet, gut microbiota, and sedentary lifestyle. NAFLD is often associated with obesity, type 2 diabetes, and dyslipidemia.
NAFLD is often silent, discovered incidentally during routine blood tests or imaging. However, a definitive diagnosis requires a liver biopsy, the gold standard for assessing liver histology. Non-invasive diagnostic strategies, such as ultrasound, elastography, and serum biomarkers, are also used to estimate liver fat content and fibrosis.
Current therapeutic strategies for NAFLD focus on lifestyle modifications, including diet and exercise. Pharmacological interventions are reserved for patients with NASH and significant fibrosis. These include insulin sensitizers, antioxidants, and lipid-lowering agents. Emerging therapies, such as FXR agonists and GLP-1R agonists, are showing promise in clinical trials.
NAFLD is a complex disease with multifactorial causes and a broad spectrum of clinical manifestations. Early identification and intervention are crucial to prevent progression to more severe liver disease. While lifestyle modification remains the cornerstone of management, advances in pharmacological therapies offer hope for more effective treatment options in the future. As our understanding of NAFLD continues to evolve, so too must our strategies for diagnosis and treatment.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation